Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
Hand-out
Press Releases
November 7, 2024

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions and

bradford

The Bradford Era

More by this Author
Local & Social